US Patent Issued to Industry-University Cooperation Foundation Hanyang University Erica Campus on Nov. 18 for "Imidazole derivative expressing FLT3 inhibitory activity, and use thereof" (South Korean Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,473,278, issued on Nov. 18, was assigned to Industry-University Cooperation Foundation Hanyang University Erica Campus (Gyeonggi-do, South Korea).

"Imidazole derivative expressing FLT3 inhibitory activity, and use thereof" was invented by Jung Mi Hah (Seoul, South Korea) and Da Seul Im (Gyeonggi-do, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a novel benzimidazole derivative having fms-like tyrosine kinase 3 (FLT3) inhibitory activity, and a use thereof. A novel benzimidazole derivative or a pharmaceutically acceptable salt thereof, according to the present invention, exhibits excellent inhibitory activity...